Taylor A J, Hotchkiss D, Morse R W, McCabe J
Department of Medicine, Walter Reed Army Medical Center, Walter Reed Army Institute of Research, Washington, DC 20307-5001, USA.
Chest. 1998 Dec;114(6):1570-4. doi: 10.1378/chest.114.6.1570.
IV hydration before and after cardiac catheterization is effective in preventing contrast-associated renal dysfunction for patients with mild-to-moderate renal insufficiency, but necessitates overnight hospital admission. We tested an outpatient oral precatheterization hydration strategy in comparison with overnight IV hydration.
We randomized 36 patients with renal dysfunction (serum creatinine > or = 1.4 mg/dL) undergoing elective cardiac catheterization to receive either overnight IV hydration (0.45 normal saline solution at 75 mL/h for both 12 h precatheterization and postcatheterization; n = 18) or an outpatient hydration protocol including precatheterization oral hydration (1,000 mL clear liquid over 10 h) followed by 6 h of IV hydration (0.45 normal saline solution at 300 mL/h) beginning just before contrast exposure. The predefined primary end point was the maximal change in creatinine up to 48 h after cardiac catheterization.
The inpatient and outpatient groups were well matched for baseline characteristics and contrast volume. By protocol design, the outpatient group received a greater volume of hydration, although the net volume changes were comparable in the two groups. The maximal changes in serum creatinine in the inpatient (0.21+/-0.38 mg/dL; 95% confidence interval [CI], 0.02 to 0.39 mg/dL) and outpatient groups (0.12+/-0.23 mg/dL; 95% CI, 0.01 to 0.24 mg/dL) were comparable (p = not significant). There were no instances of protocol intolerance.
A hydration strategy compatible with outpatient cardiac catheterization is comparable to precatheterization and postcatheterization IV hydration in preventing contrast-associated changes in serum creatinine. Hospital admission for IV hydration is unnecessary before elective cardiac catheterization in the setting of mild-to-moderate renal dysfunction.
对于轻至中度肾功能不全患者,心脏导管插入术前和术后进行静脉补液可有效预防造影剂相关的肾功能不全,但需要住院过夜。我们测试了一种门诊口服导管插入术前补液策略,并与过夜静脉补液进行比较。
我们将36例接受择期心脏导管插入术的肾功能不全患者(血清肌酐≥1.4mg/dL)随机分为两组,一组接受过夜静脉补液(导管插入术前和术后12小时均以75mL/h的速度输注0.45%生理盐水;n = 18),另一组接受门诊补液方案,包括导管插入术前口服补液(10小时内饮用1000mL清亮液体),然后在造影剂注射前开始进行6小时的静脉补液(以300mL/h的速度输注0.45%生理盐水)。预先定义的主要终点是心脏导管插入术后48小时内肌酐的最大变化。
住院组和门诊组在基线特征和造影剂用量方面匹配良好。根据方案设计,门诊组接受的补液量更大,尽管两组的净补液量变化相当。住院组(0.21±0.38mg/dL;95%置信区间[CI],0.02至0.39mg/dL)和门诊组(0.12±0.23mg/dL;95%CI,0.01至0.24mg/dL)血清肌酐的最大变化相当(p = 无显著性差异)。没有出现方案不耐受的情况。
与门诊心脏导管插入术兼容的补液策略在预防造影剂相关的血清肌酐变化方面与导管插入术前和术后静脉补液相当。在轻至中度肾功能不全的情况下,择期心脏导管插入术前无需住院进行静脉补液。